#Biopharmaceuticals #Neuroscience #HealthcareInnovation
www.benzinga.com
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Xenon Pharmaceuticals (NASDAQ:XENE)
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.
#GeneticMedicine #Biopharmaceuticals #Leadership
www.benzinga.com
ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors
WALTHAM, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced the appointment of Christopher Murphy as Chief Executive Officer (CEO) and member of its Board of Directors.
#Pelthos #Xeglyze #Biopharmaceuticals
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze庐 (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older
DURHAM, N.
#Pelthos #Xeglyze #Biopharmaceuticals
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze庐 (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older
DURHAM, N.
#Pelthos #Xeglyze #Biopharmaceuticals
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze庐 (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older
DURHAM, N.
#Biopharmaceuticals #GeneticDiseases #HealthcareConference
www.benzinga.com
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - BridgeBio Pharma (NASDAQ:BBIO)
PALO ALTO, Calif. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.
#Biopharmaceuticals #LiverDisease #FDAApproval
www.benzinga.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Altimmune (NASDAQ:ALT)
GAITHERSBURG, Md. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.
#Biopharma #Neuroscience #ClinicalTrials
www.benzinga.com
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass.
#Biopharma #Neuroscience #ClinicalTrials
www.benzinga.com
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass.
#biopharmaceuticals #cancerresearch #clinicaltrials
www.nasdaq.com
HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer
(RTTNews) - HUTCHMED (China) Ltd (HCM, HCM. L,0013. HK), a commercial-stage, biopharmaceutical company, announced on Monday that it has commenced the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib combined with camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma or PDAC in China.
